1-5 of 5
Lixia Ma
Close
Sort by
Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU
Journal: Blood
Blood (2023) 142 (Supplement 1): 6922.
https://doi.org/10.1182/blood-2023-177836
Published: 2023
Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Lixia Ma, Xiaoyan Ke, Kai HU
Journal: Blood
Blood (2023) 142 (Supplement 1): 3434.
https://doi.org/10.1182/blood-2023-184412
Published: 2023
Journal Articles

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Shaomei Feng, Teng Xu, Haidi Liu, Peihao Zheng, Lixia Ma, Hui SHI, Tong Wu, Fan Yang, Kai HU, Xiaoyan Ke
Journal: Blood
Blood (2023) 142 (Supplement 1): 4638.
https://doi.org/10.1182/blood-2023-182797
Published: 2023
Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 7548–7549.
https://doi.org/10.1182/blood-2022-168018
Published: 2022
Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10384–10385.
https://doi.org/10.1182/blood-2022-164446
Published: 2022